HOME
ABOUT US
Company Profile
Management Team
Corporate Culture
SAB
Milestones
R & D
Pipeline
Areas of Focus
Strategy
NEWS CENTER
News Center
PARTNERS
Partners
INVESTORS
Investors
CAREERS
Join Us
Employee Benefits
CONTACT
Contact
中文|EN
Company Profile
ABOUT US
Guangdong Raynovent Biotech Co., Ltd. ("Raynovent") is a sino-foreign joint venture focused on developing and commercializing innovative therapies for respiratory and metabolic diseases. Founded in October 2018 and headquartered in Huangpu District, Guangzhou, Raynovent is a controlling subsidiary of A-share listed Guangdong Zhongsheng Pharmaceutical Co., Ltd.
READ MORE
NEWS CENTER
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatoh
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2026/05/08 News Center
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
2026/05/06 News Center
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
2026/05/06 News Center
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026/05/06 News Center
Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!
Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!
2026/05/06 News Center
National Investigator Meeting for Onradivir Granules/Tablets Phase III Clinical Studies in Children and Adolescents with Influenza A Successfully Conc
National Investigator Meeting for Onradivir Granules/Tablets Phase III Clinical Studies in Children and Adolescents with Influenza A Successfully Concluded
2026/05/06 News Center
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatoh
Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2026/05/08 News Center
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!
2026/05/06 News Center
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!
2026/05/06 News Center
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026 Year-Opening Success! RAY1225 Injection Efficiently Completes Enrollment Target in Phase III Clinical Trial for Monotherapy in Type 2 Diabetes
2026/05/06 News Center
Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!
Double Victory! Onradivir Achieves Enrollment Completion in Two Pivotal Phase III Clinical Studies, Full-Age Protection on the Horizon!
2026/05/06 News Center
National Investigator Meeting for Onradivir Granules/Tablets Phase III Clinical Studies in Children and Adolescents with Influenza A Successfully Conc
National Investigator Meeting for Onradivir Granules/Tablets Phase III Clinical Studies in Children and Adolescents with Influenza A Successfully Concluded
2026/05/06 News Center
JOIN US
Application To: HR@Raynovent.com
Looking forward to your joining!